Morphic to Present at November Investor Conferences
November 10, 2023 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
August 29, 2023 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic to Present at the Jefferies Global Healthcare Conference
June 06, 2023 16:05 ET
|
Morphic Therapeutic
WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 05, 2023 10:30 ET
|
Morphic Therapeutic
WALTHAM, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (“Morphic”), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic...
Morphic Therapeutic Announces Pricing of $240.0 Million Public Offering
May 03, 2023 00:13 ET
|
Morphic Therapeutic
WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious...
Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023
April 24, 2023 16:01 ET
|
Morphic Therapeutic
WALTHAM, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Therapeutic to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
January 05, 2022 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Participation in Upcoming Investor Conferences
September 03, 2020 16:30 ET
|
Morphic Therapeutic
WALTHAM, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces that AbbVie Exercises License Option to αvβ6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases
August 25, 2020 06:30 ET
|
Morphic Therapeutic
AbbVie to pay Morphic license fee of $20 million, with future potential milestones and royalties AbbVie to lead further development and commercialization WALTHAM, Mass., Aug. 25, 2020 (GLOBE...
Morphic Announces Corporate Highlights and Second Quarter 2020 Financial Results
August 10, 2020 07:00 ET
|
Morphic Therapeutic
Company’s first IND accepted by FDA for MORF-057 in IBDPhase 1 study expected to begin in third-quarter 2020Positive data presented at DDW 2020 further support MORF-057 preclinical profile WALTHAM,...